Business
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Company also announces Marketing Engagement VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / Onco-Innovations Limited (CBOECA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the execution of an engagement ...
About this update from Onconetix, Inc.
[{"type":"text","content":"Company also announces Marketing Engagement","length":43,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / Onco-Innovations Limited (CBOECA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the execution of an engagement agreement with Research & Development Incentives Partners ("RDI Partners"), and the formation of Onco-Innovations AU Pty. Ltd. ("ONCO AU") as a wholly owned Australian subsidiary of the Company.","length":449,"tagName":"p"},{"type":"text","content":"Through the engagement with RDI Partners and the formation of its Australian subsidiary, Onco-Innovations is working towards implementing a structured operational framework to support its planned Phase I development activities in the region. This framework includes establishing and governing ONCO AU as the Company's local Australian operating entity while positioning potential eligibility for Australia's 43.5% R&D Tax Incentive program for qualifying research and development activities. The initiative also supports preparation for submission to a Human Research Ethics Committee (HREC) and progression through the Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) pathway, while aligning with financial governance practices, regulatory compliance requirements, and public-company reporting standards. Together, these steps provide scalable operational infrastructure designed to support the Company's current clinical objectives and potential future global expansion.","length":1012,"tagName":"p"},{"type":"text","content":"Australia offers a streamlined pathway for early-phase clinical trials, including the Clinical Trial Notification (CTN) scheme, efficient ethics approval processes, and a globally recognized regulatory environment. Onco-Innovations' strategy is designed to leverage these advantages while maintaining rigorous scientific, operational, and governance standards as the Company advances its development program.","length":412,"tagName":"p"},{"type":"text","content":"The engagement with RDI Partners supports disciplined financial oversight as the Company advances its Phase I program, including structured documentation and eligibility assessment related to Australian R&D tax incentives, com...